Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression

Vaccine

Volumn 32, Issue 6, 2014, Pages 717-724

  Johnson, Matthew J ^a,b,e   Björkström, Niklas K ^c   Petrovas, Constantinos ^a   Liang, Frank ^a,c   Gall, Jason G D ^d   Loré, Karin ^a,c   Koup, Richard A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GENVEC INC   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Adenovirus; RAd28; RAd35

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; RECOMBINANT ADENOVIRUS VECTOR 28; RECOMBINANT ADENOVIRUS VECTOR 35; RECOMBINANT ADENOVIRUS VECTOR 5; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL LOSS; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOGENICITY; INNATE IMMUNITY; LOSS OF VECTOR INSERT EXPRESSION; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADENOVIRUS; RAD28; RAD35;

ADENOVIRIDAE; ANTIGENS, CD14; APOPTOSIS; CELLS, CULTURED; GENETIC VECTORS; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MONOCYTES;

EID: 84892963268     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.055     Document Type: Article

References (26)

1. Smed-Sorensen A., Loré K., Vasudevan J., Louder M.K., Andersson J., Mascola J.R., et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol 2005, 79(14):8861-8869.
2. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W.B., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850.
3. Abbink P., Lemckert A.A.C., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81(9):4654-4663.
4. Quinn K.M., Da Costa A., Yamamoto A., Berry D., Lindsay R.W.B., Darrah P.A., et al. Comparative analysis of the magnitude, phenotype and protective capacity of SIV gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenovirus vector immunisation. J Immunol 2013, 190(6):2720-2735.
5. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18(8):1213-1216.
6. Kahl C.A., Bonnell J., Hiriyanna S., Fultz M., Nyberg-Hoffman C., Chen P., et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 2010, 28(35):5691-5702.
7. Fowlkes D.M., Shenk T. Transcriptional control regions of the adenovirus VAI RNA gene. Cell 1980, 22(2):405-413.
8. Shayakhmetov D.M., Li Z.Y., Ternovoi V., Gaggar A., Gharwan H., Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 2003, 77(6):3712-3723.
9. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009, 19(3):165-178.
10. Zheng H., Jin B., Henrickson S.E., Perelson A.S., Von Andrian U.H., Chakraborty A.K. How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol 2008, 28(12):4040-4051.
11. Johnson M.J., Petrovas C., Yamamoto T., Lindsay R.W.B., Loré K., Gall J.G.D., et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol 2012, 188(12):6109-6118.
12. Hamilton M.M., Byrnes G.A., Gall J.G., Brough D.E., King C.R., Wei L.L. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 2008, 14:2535-2546.
13. Brough D.E., Lizonova A., Hsu C., Kulesa V.A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996, 70(9):6497-6501.
14. Bryceson Y.T., Fauriat C., Nunes J.M., Wood S.M., Björkström N.K., Long E.O., et al. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol 2010, 612:17.
15. Pahl J.H.W., Verhoeven D.H.J., Kwappenberg K., Vellinga J., Lankester A.C., van Tol M.J.D., et al. Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling. Mol Immunol 2012.
16. Zhu J., Huang X., Yang Y. A critical role for type I IFN-dependent NK Cell activation in innate immune elimination of adenoviral vectors in vivo. Mol Ther 2008, 16(7):1300-1307.
17. Shiow L.R., Rosen D.B., Brdičková N., Xu Y., An J., Lanier L.L., et al. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006, 440(7083):540-544.
18. Loré K., Smed-Sorensen A., Vasudevan J., Mascola J.R., Koup R.A. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 2005, 201(12):2023-2033.
19. Finn J.D., Bassett J., Millar J.B., Grinshtein N., Yang T.C., Parsons R., et al. Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol 2009, 83(23):12027-12036.
20. Ren G., Su J., Zhao X., Zhang L., Zhang J., Roberts A.I., et al. Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-gamma and nitric oxide. J Immunol 2008, 181(5):3277-3284.
21. Tassiulas I., Park-Min K.H., Hu Y., Kellerman L., Mevorach D., Ivashkiv L.B. Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages. Hum Immunol 2007, 68(3):156-164.
22. Kim S.J., Gershov D., Ma X., Brot N., Elkon K.B. Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann N Y Acad Sci 2006, 987(1):68-78.
23. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390(6658):350-351.
24. Henrickson S.E., Mempel T.R., Mazo I.B., Liu B., Artyomov M.N., Zheng H., et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol 2008, 9(3):282-291.
25. Leignadier J., Labrecque N. Epitope density influences CD8+ memory T cell differentiation. PLoS ONE 2010, 5(10):e13740.
26. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.